Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Grand Pharmaceutical Group Limited ( (HK:0512) ) is now available.
Grand Pharmaceutical Group has announced that Neffy, the world’s first adrenaline nasal spray for emergency treatment of type I allergic reactions, has obtained a drug registration certificate from China’s National Medical Products Administration, giving the Group exclusive commercialization rights in mainland China and non-exclusive rights in Hong Kong, with plans for localized production within 24 months. As the first non-injectable adrenaline product for severe allergic reactions, Neffy is expected to significantly improve access to life-saving treatment outside hospitals in China—where adrenaline use remains low—bolstering the Group’s emergency-care portfolio and potentially becoming a new growth engine for its cerebro-cardiovascular emergency segment through rapid penetration into home, school and travel settings supported by its existing distribution and academic promotion capabilities.
The most recent analyst rating on (HK:0512) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Grand Pharmaceutical Group Limited stock, see the HK:0512 Stock Forecast page.
More about Grand Pharmaceutical Group Limited
Grand Pharmaceutical Group Limited is a Bermuda-incorporated pharmaceutical company focused on cerebro-cardiovascular emergency care and chronic disease management in China. It is designated as a national essential drug production base and an emergency medicines manufacturer for national reserve, with over 30 emergency-related varieties, many of which are included in China’s national emergency and shortage drug catalogues. Its emergency portfolio spans in-hospital, pre-hospital and civilian scenarios, while core chronic products such as Nengqilang, Limetone eplerenone tablets and Herbesser occupy leading positions in their respective market segments.
Average Trading Volume: 6,010,035
Technical Sentiment Signal: Buy
Current Market Cap: HK$28.68B
For a thorough assessment of 0512 stock, go to TipRanks’ Stock Analysis page.